Lecture 1 - Pharmacogenomics Flashcards

1
Q

Pharmacogenetics

A

the study of sequence variation (single nucleotide polymorphism - SNPs) in individual genes, and the role sequence variation plays in determining an individual’s metabolism of drugs (pharmacokinetic) and response to drugs (pharmacodynamic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pharmacokinetic vs pharmacodynamic

A

kinetic: metabolism of drugs
dynamic: response to drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which group has the lowest alcohol abuse rate and why?

A

asians d/t inactive allele (SNP) of acetaldehyde dehydrogenase (genetic disulfiram)

this causes flushing (asian glow) and N/V/HA, hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Where is the bulk of acetalydehyde dehydrogenase activity in the body?

A

ALDH2 in the mitochondria (vs ALDH1 found in cytosol)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Of individuals that abuse alcohol, which group is more likely to develop esophageal cancer?

A

asians

Since there is no ALDH there is a build up of acid aldehyde which modifies DNA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is a SNP?

A

a DNA sequence variation that occurs when a single nucleotide (A, T, C, or G) in the genome differs between two individuals

SNPs make up about ~80% of all human variation

for it to be considered and not a SNP, it must occur in at least 1% of the population

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Where are the most SNPs found?

A

integrenic region –between region genes –impact on phenotype

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the different locations of SNPs are found?

A

protein coding region of genes, exon-intron boundaries of genes, tandem repeats in promoter regions, and intergenic regions

coding regions, exon-intron boundaries, promoter regions can predispose individual to disease, or influence response to drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Synonymous vs non-synonymous SNPs?

A

synonymous = least interesting, no change to amino acid

non-synonymous (both missense/nonsense) change amino acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Monogenic vs polygenic trait

A
monogenic trait (classic mendelian inheritance) 
-bimodal/trimodal distribution 
polygenic trait (quantitative) 
-unimodal distribution with wide distribution d/t gene- environment interactions 

the general population looks like F2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does pharmacogenetics play a role in drug companies?

A

Phenotype driven or “forward genetics”

When drug companies are testing drugs, they plot adverse reactions on a graph, bimodal distribution means its a monogenic trait so they begin to do family studies to look for the gene responsible for the adverse drug reactions –typically its d/t enzyme responsible for metabolizing the drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Nanosphere test

A

tests which pts will have adverse reactions to warfarin based on VKORC1 and CYP2C9 alleles

FDA approved before starting Warfarin

will determine dosing of warfarin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Most responses to drugs, and certainly most disease, are ___monogenic or polygenic?

A

polygenic (2 or more polymorphic genes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the different classes of SNPs and their effects on drugs?

A

pharmacokinetics:

  • drug metabolizing enzymes
  • drug transporters

pharmacodynamics:
- target proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the examples of drugs involved in pharmacogenetics?

A

EtOH
Pheytoin
Warfarin
5-FU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Phenytoin

A

response to dictated by polymorphisms in all 3 classes (metabolizing, transporters, target)

1) SNP in CYP2C9, CYP2C19 (increase serum levels –> ADRs)
2) SNP in MDR1 gene promoter (poor therapeutic response)
3) SNP in voltage gated Na+ (poor therapeutic response)

17
Q

Warfarin

A

the second most common ER visit related to ADRs (behind insulin)

30% of pts are at higher risk for bleeding d/t excessive levels of warfarin in blood

activated in liver by CYP2C9

18
Q

VKORK1

A

warfarin inhibits this to stop activation of vitamin K

19
Q

5-FU

A
dihydropyrmidine dehydrogenase (DPD)  --polymorphic 
Thymidylate synthase (TS) - polymorphic 

DPD found in the liver to inactivate 5-FU –> can lead to increased 5FU which can lead to myelopsuppression

TS:
2 tandem repeat –> decrease TS –> good for the drug drug
3 tandem repeat –> increase TS –> bad for the drug

20
Q

CYP2D6

A

most important P450 enzyme
~50% of ADRs are d/t polymorphic CYP2D6

decrease action:

1) needed for metabolism (increase serum levels)
2) prodrug –> needed for activation (non-responsive)

amplification:
1) inactivation too rapid (non-responsive)
2) prodrug activation too rapid (increase risk of ADRs, increased serum levels)

21
Q

Codeine

A

2 inactive forms of CYP2D6: poor metabolizer –give alternative opioid such as hydrocodone or oxycodone

1 inactive YP2D6 (ultra-metabolizer) –risk of respiratory depression

22
Q

Pharmacogenomics

A

looks at ALL sequenced variance

-studies include environment- gene interactions